Access the full text.
Sign up today, get DeepDyve free for 14 days.
F Cardoso (2018)
10.1093/annonc/mdx651Ann Oncol, 29
AM Burga, O Fadare, RA Lininger, FA Tavassoli (2006)
Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 casesVirchows Arch, 449
G Masci (2011)
10.1093/annonc/mdr005Ann Oncol, 22
F Marchal (2009)
10.1245/s10434-009-0327-6Ann Surg Oncol, 16
IS Fentiman, A Fourquet, GN Hortobagyi (2006)
Male breast cancerLancet, 367
M Stepnik, S Spryszynska, A Gorzkiewicz, M Ferlinska (2017)
Cytotoxicity of anticancer drugs and PJ-34 (poly(ADP-ribose)polymerase-1 (PARP-1) inhibitor) on HL-60 and Jurkat cellsAdv Clin Exp Med, 26
CS Bagley (1987)
10.1097/00000421-198702000-00013Am J Clin Oncol, 10
F Giotta, L Acito, G Candeloro, P Medico, G Gadaleta-Caldarola, G Giordano (2016)
Eribulin in male patients with breast cancer: the first report of clinical outcomesOncologist, 21
TM Severson (2017)
10.1530/ERC-16-0225Endocr Relat Cancer, 24
CE Scott-Conner (1999)
10.1016/S0039-6060(99)70135-2Surgery, 126
P Rizzolo, V Silvestri, S Tommasi, R Pinto, K Danza, M Falchetti (2013)
Male breast cancer: genetics, epigenetics, and ethical aspectsAnn Oncol, 24
WS Symmers (1968)
Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristicsBr Med J, 2
M Falchetti, R Lupi, P Rizzolo, K Ceccarelli, I Zanna, V Calo (2008)
BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer casesBreast Cancer Res Treat, 110
A Agrawal, AA Ayantunde, R Rampaul, JF Robertson (2007)
Male breast cancer: a review of clinical managementBreast Cancer Res Treat, 103
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez (2015)
DNA-repair defects and olaparib in metastatic prostate cancerN Engl J Med, 373
LC Collins, KS Cole, JD Marotti, R Hu, SJ Schnitt, RM Tamimi (2011)
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health StudyMod Pathol, 24
MA Vermeulen (2017)
10.1016/j.ejca.2017.01.034Eur J Cancer, 82
LA Korde, JA Zujewski, L Kamin, S Giordano, S Domchek, WF Anderson (2010)
Multidisciplinary meeting on male breast cancer: summary and research recommendationsJ Clin Oncol, 28
IE Young, KM Kurian, C Annink, IH Kunkler, VA Anderson, BB Cohen (1999)
A polymorphism in the CYP17 gene is associated with male breast cancerBr J Cancer, 81
L Ottini (2010)
10.1016/j.critrevonc.2009.04.003Crit Rev Oncol Hematol, 73
RB Everson, ME Lippman, EB Thompson, WL McGuire, JL Wittliff, ER Sombre (1980)
Clinical correlations of steroid receptors and male breast cancerCancer Res, 40
L Lauro, L Pizzuti, M Barba, D Sergi, I Sperduti, M Mottolese (2015)
Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective studyJ Exp Clin Cancer Res, 34
J McClure, C Higgins (1951)
Bilateral carcinoma of male breast after estrogen therapyJ Am Med Assoc, 146
MG Joshi (1996)
10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#Cancer, 77
N Mauras, KO O’Brien, KO Klein, V Hayes (2000)
Estrogen suppression in males: metabolic effectsJ Clin Endocrinol Metab, 85
JS Parker (2009)
10.1200/JCO.2008.18.1370J Clin Oncol, 27
Y Imamura, MD Sadar (2016)
Androgen receptor targeted therapies in castration-resistant prostate cancer: bench to clinicInt J Urol, 23
R Hultborn, C Hanson, I Kopf, I Verbiene, E Warnhammar, A Weimarck (1997)
Prevalence of Klinefelter’s syndrome in male breast cancer patientsAnticancer Res, 17
MB El-Tamer, IK Komenaka, A Troxel, H Li, KA Joseph, BA Ditkoff (2004)
Men with breast cancer have better disease-specific survival than womenArch Surg, 139
KJ Ruddy, EP Winer (2013)
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorshipAnn Oncol, 24
N Arnould, O Pouget, M Gharbi, JP Brettes (2006)
Breast cancer in men: are there similarities with breast cancer in women?Gynecol Obstet Fertil, 34
F Cardoso, A Costa, E Senkus, M Aapro, F Andre, CH Barrios (2017)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Ann Oncol, 28
V Silvestri (2010)
10.1007/s10549-010-0797-zBreast Cancer Res Treat, 122
G Masci, C Gandini, M Zuradelli, P Pedrazzoli, R Torrisi, FR Lutman (2011)
Fulvestrant for advanced male breast cancer patients: a case seriesAnn Oncol, 22
JR Haba Rodríguez de la (2009)
10.1093/annonc/mdp413Ann Oncol, 20
V Silvestri, P Rizzolo, I Zanna, M Falchetti, G Masala, S Bianchi (2010)
PALB2 mutations in male breast cancer: a population-based study in Central ItalyBreast Cancer Res Treat, 122
JS Parker, AC Peterson, IC Tudor, J Hoffman, H Uppal (2015)
A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBCJ Clin Oncol, 33
H Eggemann (2013)
10.1007/s10549-012-2355-3Breast Cancer Res Treat, 137
SC Doebar (2017)
10.1038/modpathol.2016.229Mod Pathol, 30
JD Norris (2017)
10.1172/JCI87328J Clin Invest, 127
B Rahim, R O’Regan (2017)
AR signaling in breast cancerCancers (Basel), 9
C Rudlowski (2008)
10.1159/000136825Breast Care, 3
IE Young (1999)
10.1038/sj.bjc.6690663Br J Cancer, 81
MA Vermeulen, L Slaets, F Cardoso, SH Giordano, K Tryfonidis, PJ Diest (2017)
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramEur J Cancer, 82
Y Imamura (2016)
10.1111/iju.13137Int J Urol, 23
K Gudmundsdottir (2003)
10.1038/sj.bjc.6600839Br J Cancer, 88
I Johansson, C Nilsson, P Berglund, M Lauss, M Ringner, H Olsson (2012)
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarkerBreast Cancer Res, 14
JS Parker, M Mullins, MC Cheang, S Leung, D Voduc, T Vickery (2009)
Supervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol, 27
VW Setiawan, FR Schumacher, CA Haiman, DO Stram, D Albanes, D Altshuler (2007)
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)Cancer Epidemiol Biomarkers Prev, 16
F Karami, P Mehdipour (2013)
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancerBiomed Res Int, 2013
SC Doebar, L Slaets, F Cardoso, SH Giordano, JM Bartlett, K Tryfonidis (2017)
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramMod Pathol, 30
R Kornegoor, CB Moelans, AH Verschuur-Maes, M Hogenes, PC Bruin, JJ Oudejans (2012)
Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplificationBreast Cancer Res, 14
PF Trunet, P Mueller, AS Bhatnagar, I Dickes, G Monnet, G White (1993)
Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjectsJ Clin Endocrinol Metab, 77
WL Donegan (1998)
10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-RCancer, 83
MHSE Darkeh, E Azavedo (2014)
Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approachesInt J Clin Med, 5
J Doyen, A Italiano, R Largillier, JM Ferrero, X Fontana, A Thyss (2010)
Aromatase inhibition in male breast cancer patients: biological and clinical implicationsAnn Oncol, 21
LC Collins (2011)
10.1038/modpathol.2011.54Mod Pathol, 24
D Ford, DF Easton, M Stratton, S Narod, D Goldgar, P Devilee (1998)
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage ConsortiumAm J Hum Genet, 62
M Liang (2018)
10.1007/s40291-018-0344-xMol Diagn Ther
H Visram (2010)
10.3747/co.v17i5.631Curr Oncol, 17
JR Weiss, KB Moysich, H Swede (2005)
Epidemiology of male breast cancerCancer Epidemiol Biomarkers Prev, 14
D Ford (1998)
10.1086/301749Am J Hum Genet, 62
M Pritzlaff, P Summerour, R McFarland, S Li, P Reineke, JS Dolinsky (2017)
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected resultsBreast Cancer Res Treat, 161
DR Cochrane, S Bernales, BM Jacobsen, DM Cittelly, EN Howe, NC D’Amato (2014)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamideBreast Cancer Res, 16
MB El-Tamer (2004)
10.1001/archsurg.139.10.1079Arch Surg, 139
Q Wu, J Li, S Zhu, J Wu, X Li, Q Liu (2016)
Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtypeOncotarget, 7
J Mateo (2015)
10.1056/NEJMoa1506859N Engl J Med, 373
R Gennari, G Curigliano, BA Jereczek-Fossa, S Zurrida, G Renne, M Intra (2004)
Male breast cancer: a special therapeutic problem. Anything new? (Review)Int J Oncol, 24
I Johansson (2011)
10.1007/s10549-010-1262-8Breast Cancer Res Treat, 129
LC Harlan, JA Zujewski, MT Goodman, JL Stevens (2010)
Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survivalCancer, 116
MHSE Darkeh (2014)
10.4236/ijcm.2014.517138Int J Clin Med, 5
JR Weiss (2005)
10.1158/1055-9965.20.14.1Cancer Epidemiol Biomarkers Prev, 14
M Liang, Y Zhang, C Sun, FK Rizeq, M Min, T Shi (2018)
Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysisMol Diagn Ther
TM Severson, W Zwart (2017)
A review of estrogen receptor/androgen receptor genomics in male breast cancerEndocr Relat Cancer, 24
CS Bagley, MN Wesley, RC Young, ME Lippman (1987)
Adjuvant chemotherapy in males with cancer of the breastAm J Clin Oncol, 10
Y Kim (2017)
10.7150/ijbs.17240Int J Biol Sci, 13
M Stepnik (2017)
10.17219/acem/60848Adv Clin Exp Med, 26
M Falchetti (2008)
10.1007/s10549-007-9689-2Breast Cancer Res Treat, 110
J McClure (1951)
10.1001/jama.1951.03670010011002J Am Med Assoc, 146
A Gucalp (2013)
10.1158/1078-0432.CCR-12-3327Clin Cancer Res, 19
CE Scott-Conner, PR Jochimsen, HR Menck, DJ Winchester (1999)
An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patientsSurgery, 126
F Cardoso, JMS Bartlett, L Slaets, CHM Deurzen, E Leeuwen-Stok, P Porter (2018)
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramAnn Oncol, 29
VW Setiawan (2007)
10.1158/1055-9965.EPI-07-0589Cancer Epidemiol Biomarkers Prev, 16
JD Norris, SJ Ellison, JG Baker, DB Stagg, SE Wardell, S Park (2017)
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerJ Clin Invest, 127
IS Fentiman (2006)
10.1016/S0140-6736(06)68226-3Lancet, 367
MP Humphries (2017)
10.1038/srep45293Sci Rep, 7
F Marchal, M Salou, C Marchal, A Lesur, E Desandes (2009)
Men with breast cancer have same disease-specific and event-free survival as womenAnn Surg Oncol, 16
JS Parker (2015)
10.1200/jco.2015.33.15_suppl.1083J Clin Oncol, 33
F Karami (2013)
10.1155/2013/928562Biomed Res Int, 2013
MG Joshi, AK Lee, M Loda, MG Camus, C Pedersen, GJ Heatley (1996)
Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcomeCancer, 77
H Eggemann, A Ignatov, BJ Smith, U Altmann, G Minckwitz, FW Rohl (2013)
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patientsBreast Cancer Res Treat, 137
Q Wu (2016)
10.18632/oncotarget.12052Oncotarget, 7
UY Arslan, B Oksuzoglu, N Ozdemir, S Aksoy, N Alkis, A Gok (2012)
Outcome of non-metastatic male breast cancer: 118 patientsMed Oncol, 29
SH Giordano, CP Schröder, C Poncet, E Leeuwen-Stok, B Linderholm, MH Abreu (2018)
Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2–07: baseline results from the prospective registryCan Res, 78
A Papa (2016)
10.1186/s12967-016-1027-1J Transl Med, 14
JR Haba Rodríguez, I Porras Quintela, G Pulido Cortio, M Berciano Guerrero, E Aranda (2009)
Fulvestrant in advanced male breast cancerAnn Oncol, 20
MP Humphries, S Sundara Rajan, H Honarpisheh, G Cserni, J Dent, L Fulford (2017)
Characterisation of male breast cancer: a descriptive biomarker study from a large patient seriesSci Rep, 7
DR Cochrane (2014)
10.1186/bcr3599Breast Cancer Res, 16
K Gudmundsdottir, S Thorlacius, JG Jonasson, BF Sigfusson, L Tryggvadottir, JE Eyfjord (2003)
CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 statusBr J Cancer, 88
CI Li, BO Anderson, JR Daling, RE Moe (2003)
Trends in incidence rates of invasive lobular and ductal breast carcinomaJAMA, 289
AM Burga (2006)
10.1007/s00428-006-0305-3Virchows Arch, 449
TF Anelli, A Anelli, KN Tran, DE Lebwohl, PI Borgen (1994)
Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patientsCancer, 74
H Visram, F Kanji, SF Dent (2010)
Endocrine therapy for male breast cancer: rates of toxicity and adherenceCurr Oncol, 17
LA Korde (2010)
10.1200/JCO.2009.25.5729J Clin Oncol, 28
J Rivero, EC Kohn (2017)
PARP inhibitors: the cornerstone of DNA repair-targeted therapiesOncology (Williston Park), 31
JV Kiluk (2011)
10.1111/j.1524-4741.2011.01148.xBreast J, 17
TF Anelli (1994)
10.1002/1097-0142(19940701)74:1<74::AID-CNCR2820740113>3.0.CO;2-#Cancer, 74
S Piscuoglio (2016)
10.1158/1078-0432.CCR-15-2840Clin Cancer Res, 22
WL Donegan, PN Redlich, PJ Lang, MT Gall (1998)
Carcinoma of the breast in males: a multiinstitutional surveyCancer, 83
WF Anderson, I Jatoi, J Tse, PS Rosenberg (2010)
Male breast cancer: a population-based comparison with female breast cancerJ Clin Oncol, 28
A Papa, D Caruso, M Strudel, S Tomao, F Tomao (2016)
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentJ Transl Med, 14
P Rizzolo (2013)
10.1093/annonc/mdt316Ann Oncol, 24
S Piscuoglio, CK Ng, MP Murray, E Guerini-Rocco, LG Martelotto, FC Geyer (2016)
The genomic landscape of male breast cancersClin Cancer Res, 22
KJ Vogel Postula, LM Andolina, K Theobald, AK McGill, E Sutcliffe, KJ Arvai (2018)
The role of multi-gene hereditary cancer panels in male patients with breast cancerCancer Res, 78
LC Harlan (2010)
10.1002/cncr.25153Cancer, 116
F Giotta (2016)
10.1634/theoncologist.2016-0022Oncologist, 21
A Yoney, A Kucuk, M Unsal (2009)
Male breast cancer: a retrospective analysisCancer Radiother, 13
MH Greene (1997)
10.4065/72.1.54Mayo Clin Proc, 72
M Pritzlaff (2017)
10.1007/s10549-016-4085-4Breast Cancer Res Treat, 161
JL Christenson (2018)
10.1007/s12672-017-0314-5Horm Canc, 9
B Cutuli (2007)
10.1517/14656566.8.2.193Expert Opin Pharmacother, 8
A Yoney (2009)
10.1016/j.canrad.2008.11.011Cancer Radiother, 13
I Johansson, C Nilsson, P Berglund, C Strand, G Jonsson, J Staaf (2011)
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancerBreast Cancer Res Treat, 129
CI Li (2003)
10.1001/jama.289.11.1421JAMA, 289
SH Giordano, DS Cohen, AU Buzdar, G Perkins, GN Hortobagyi (2004)
Breast carcinoma in men: a population-based studyCancer, 101
WS Symmers (1968)
10.1136/bmj.2.5597.83Br Med J, 2
WF Anderson (2010)
10.1200/JCO.2009.23.8162J Clin Oncol, 28
B Rahim (2017)
10.3390/cancers9030021Cancers (Basel), 9
J Doyen (2010)
10.1093/annonc/mdp450Ann Oncol, 21
MH Greene (1997)
Genetics of breast cancerMayo Clin Proc, 72
N Arnould (2006)
10.1016/j.gyobfe.2006.03.014Gynecol Obstet Fertil, 34
A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey (2013)
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerClin Cancer Res, 19
R Kornegoor (2012)
10.1186/bcr3220Breast Cancer Res, 14
V Silvestri, D Barrowdale, AM Mulligan, SL Neuhausen, S Fox, BY Karlan (2016)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Breast Cancer Res, 18
L Lauro Di (2015)
10.1186/s13046-015-0143-8J Exp Clin Cancer Res, 34
F Cardoso (2017)
10.1093/annonc/mdx036Ann Oncol, 28
Y Kim, A Kim, A Sharip, A Sharip, J Jiang, Q Yang (2017)
Reverse the resistance to PARP inhibitorsInt J Biol Sci, 13
SH Giordano (2004)
10.1002/cncr.20312Cancer, 101
UY Arslan (2012)
10.1007/s12032-011-9978-9Med Oncol, 29
A Agrawal (2007)
10.1007/s10549-006-9356-zBreast Cancer Res Treat, 103
JV Kiluk, MC Lee, CK Park, T Meade, S Minton, E Harris (2011)
Male breast cancer: management and follow-up recommendationsBreast J, 17
JL Christenson, JB Trepel, YA Haythem, S Lee, JR Eisner, ES Baskni-Bey (2018)
Harnessing a different dependency: how to identify and target androgen receptor-positive versus quadruple-negative breast cancerHorm Canc, 9
V Silvestri (2016)
10.1186/s13058-016-0671-yBreast Cancer Res, 18
B Cutuli (2007)
Strategies in treating male breast cancerExpert Opin Pharmacother, 8
KJ Ruddy (2013)
10.1093/annonc/mdt025Ann Oncol, 24
I Johansson (2012)
10.1186/bcr3116Breast Cancer Res, 14
Purpose Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapolated from data available from clinical trials enrolling female BC patients. Methods We review the epidemiology, risk factors, prognosis, and the varied molecular and clinicopathologic features that characterize male BC. In addition, we summarize the available data for the use of systemic therapy in the treatment of male BC and explore the ongoing development of targeted therapeutic agents for the treatment of this subgroup of BCs. Results There are important biological differences between male and female BC. Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC. Additional research is warranted to better characterize male BC. To accomplish this, a multi-national consortium approach, such as the International Male Breast Cancer Program, is needed in response to the scarcity of patients. This approach allows the pooling of information from a large number of men with
Breast Cancer Research and Treatment – Springer Journals
Published: Sep 28, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.